Premium
Gender differences in demographic and clinical characteristics of patients with opioid use disorder entering a comparative effectiveness medication trial
Author(s) -
Campbell Aimee N. C.,
BarbosaLeiker Celestina,
HatchMaillette Mary,
Mennenga Sarah E.,
Pavlicova Martina,
Scodes Jennifer,
Saraiya Tanya,
Mitchell Shan G.,
Rotrosen John,
Novo Patricia,
Nunes Edward V.,
Greenfield Shelly F.
Publication year - 2018
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1111/ajad.12784
Subject(s) - opioid use disorder , buprenorphine , naltrexone , psychiatry , psychological intervention , medicine , comorbidity , substance abuse , randomized controlled trial , vulnerability (computing) , clinical psychology , opioid , receptor , computer security , computer science
Background & Objectives We investigated gender differences in individuals with opioid use disorder (OUD) receiving inpatient services and entering a randomized controlled trial comparing extended‐release naltrexone to buprenorphine. Methods Participants ( N = 570) provided demographic, substance use, and psychiatric information. Results Women were significantly younger, more likely to identify as bisexual, live with a sexual partner, be financially dependent, and less likely employed. Women reported significantly greater psychiatric comorbidity and risk behaviors, shorter duration but similar age of onset of opioid use. Discussion/Conclusions Findings underscore economic, psychiatric, and infection vulnerability among women with OUD. Scientific Significance Interventions targeting these disparities should be explored, as women may face complicated treatment initiation, retention, and recovery. (Am J Addict 2018;27:465–470)